Skinvisible (SKVI) Income from Non-Controlling Interests (2017)
Skinvisible's (SKVI) quarterly Income from Non-Controlling Interests came in at -$280.0 in Q3 2017.
Powered by 
Analysis
Skinvisible (SKVI) Income from Non-Controlling Interests (2017) Analysis & Trends
Skinvisible has disclosed Income from Non-Controlling Interests across 1 years of filings, most recently posting -$280.0 for Q3 2017.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | - |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | 3.00 Mn |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | -2.00 Mn |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | -7.00 Mn |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | 10.00 Mn |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | 39.52 Mn |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | - |
| 8 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | - |
| 9 | United Therapeutics | 20.81 Bn | 18.15 Bn | 683.80 Mn | - |
| 10 | Skinvisible | 1.08 Mn | 1.08 Mn | 5,000.00 | - |